Evotec Partner Facio Therapies achieves first-ever in vivo proof of principle in FSHD


Hamburg, Germany, 31 October 2018: 
Evotec partner Facio Therapies (“Facio”) announced today that oral treatment with one of Facio’s lead candidates results in significant reduction of the human muscle-toxic DUX4 protein in mice engrafted with human FSHD-affected muscle cells. Facio is the first in the FSHD field to achieve proof of principle in an animal model (“in vivo”).

For further information, please follow this link to Facio’s full press release: https://www.facio-therapies.com/news/facio-achieves-first-ever-in-vivo-proof-of-principle-in-fshd


About Evotec and Facio Therapies 

Since 2015, Facio and Evotec have been collaborating to identify DUX4-repressing small-molecule compounds as a potential treatment to stop the progression of FSHD, a condition with substantial unmet medical need. In 2017, Evotec became a minority partner in Facio Therapies through participation in the 2017 funding round together with Australian, European and North American members of the Facioscapulohumeral dystrophy ("FSHD") community.



Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.